Veracyte Inc (FRA:12V)
€ 32 0.6 (1.91%) Market Cap: 2.54 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 2.37 GF Score: 83/100

Veracyte Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 09:30PM GMT
Release Date Price: €23.2
Dan Delfico JPMorgan Chase;Co;Analyst

&-

Good afternoon, everybody, and welcome to the 42 Annual JPMorgan Healthcare Conference. My name is Dan Delfico, Gome, one of the associates on the healthcare banking team here today. It's my pleasure to introduce you to the Veracyte team more exactly. And Rebecca Chambers. Just a reminder that we'll do a Q&A session at the end of the presentation, and we'll have a mike coming around to a to be passed.

With that, I'll turn it over to Mark.

Marc Stapley Veracyte
Inc. - CEO

Great. Thank you, Dan. Appreciate it and thanks for having us. Hi, everyone. It's a pleasure to be here with you at this year's JPMorgan Healthcare Conference. My name is Marc Stapley, and I joined Veracyte as CEO in 2021. It's been an honor leading the team over the past 2.5 years, and I'm proud of what I believe is a very transformative approach to diagnostics in cancer.

We have a demonstrated track record of strong execution and prudent financial management, creating exceptional value for all

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot